Medpace Stock Outlook Turns on Backlog Quality and Cancellations
Medpace's near-term outlook is driven by the quality of its backlog rather than headline growth, with revenue visibility strong but booking momentum not indicating immediate acceleration. The company benefits from stable margins and high metabolic demand, but faces challenges from increased cancellations, particularly in oncology and cardiovascular programs. While backlog provides continuity, a book-to-bill ratio below 1.0X and softer requests for proposals suggest a measured growth outlook, requiring patient investors to monitor whether backlog quality and new awards can outpace cancellations without margin pressure.
Enterprise value to revenue forward of Medpace Holdings, Inc. – NASDAQ:MEDP
This article focuses on the enterprise value to revenue forward metric for Medpace Holdings, Inc. (NASDAQ: MEDP). It appears to be a financial data point presented on TradingView without additional commentary or analysis within the provided content. The surrounding text primarily consists of navigation and site information for TradingView.
MEDP - Medpace Holdings Inc Latest SEC Filings
This article provides the latest SEC filings information for Medpace Holdings Inc (MEDP), along with comprehensive financial data, key performance indicators, and company statistics. It details various financial ratios, insider and institutional ownership, profitability margins, and stock performance metrics for the company.
Here's Why Medpace Holdings (NASDAQ:MEDP) Has Caught The Eye Of Investors
Medpace Holdings (NASDAQ:MEDP) has demonstrated strong financial performance, reporting a significant return on capital employed (ROCE) of 34% and increasing its capital employed by 65%. This indicates an efficient and growing business that is effectively reinvesting its earnings. The company's ability to generate high returns on its investments explains why it is attracting investor attention.
Medpace (NASDAQ: MEDP) director converts restricted stock units into common shares
Medpace Holdings director Cornelius P. McCarthy III converted 28 restricted stock units (RSUs) into common shares, adding to his direct holdings of 10,352 shares. He still holds 56 unvested RSUs. This transaction, detailed in a Form 4 filing, is an exercise of derivative securities and not an open-market trade.
Medpace (MEDP) director Robert O. Kraft exercises 33 RSUs, holds 955 shares
Medpace Holdings, Inc. director Robert O. Kraft exercised 33 restricted stock units (RSUs) into common shares on June 30, holding 955 common shares and 64 remaining RSUs after the transaction. These RSUs are part of a 130-unit grant from November 28, 2025, vesting in four equal installments through December 31, 2026. This transaction reflects routine equity compensation rather than open-market trading.
Medpace (MEDP) director converts 36 RSUs into common shares
Medpace Holdings director Brian T. Carley converted 36 restricted stock units (RSUs) into common stock on June 30, 2026. This transaction, revealed in a Form 4 SEC filing, brings his total common stock holdings to 32,825 shares, with 71 RSUs remaining. The RSUs are part of a 143-unit grant from November 28, 2025, vesting in installments.
MEDP INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc
Bronstein, Gewirtz and Grossman, LLC has announced a class action lawsuit against Medpace Holdings, Inc. (NASDAQ:MEDP) and certain officers for alleged violations of federal securities laws. The lawsuit claims Medpace made materially false and misleading statements regarding its expected book-to-bill ratio for Q4 and H2 of fiscal year 2025. Investors who purchased Medpace securities between April 22, 2025, and February 9, 2026, are encouraged to join the lawsuit, with a deadline of June 5, 2026, to request lead plaintiff status.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Medpace Holdings, Inc. (MEDP) And Encourages Investors to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating Medpace Holdings, Inc. (NASDAQ:MEDP) for potential corporate wrongdoing. The firm encourages investors who purchased Medpace securities before April 22, 2025, and still hold them, to connect to assist with the investigation. This class action aims to recover investor capital and ensure corporate accountability, operating on a contingency fee basis.
Bronstein, Gewirtz & Grossman, LLC Encourages Medpace Holdings, Inc. (MEDP) Stockholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of Medpace Holdings, Inc. (NASDAQ:MEDP) stockholders who purchased shares before April 22, 2025. The investigation focuses on possible corporate wrongdoing by Medpace and its officers/directors. The law firm encourages affected investors to contact them for more information, emphasizing that they operate on a contingency fee basis.
Price to book forward of Medpace Holdings, Inc. – NASDAQ:MEDP
This page displays the "Price to book forward" metric for Medpace Holdings, Inc. (NASDAQ: MEDP). It appears to be a financial data point provided by TradingView, with additional data from ICE Data Services and FactSet. The page is primarily a placeholder for this specific financial indicator.
Price to sales forward of Medpace Holdings, Inc. – NASDAQ:MEDP
This article provides the "Price to sales forward" metric for Medpace Holdings, Inc. (NASDAQ: MEDP). It appears to be a financial data point from TradingView, indicating a specific valuation ratio for the company's stock.
Medpace Holdings Inc (MEDP) Valuation: PE, PB & Fair Value Analysis
Medpace Holdings Inc (MEDP) has a current valuation score of 9.87, ranking 7th out of 387 in the Biotechnology & Medical Research industry. The company's P/E ratio stands at 32.49, which is significantly below its recent high but above its recent low. However, relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed by the company.
Enterprise value to EBITDA forward of Medpace Holdings, Inc. – NASDAQ:MEDP
This article provides financial data for Medpace Holdings, Inc. (NASDAQ: MEDP), specifically focusing on its enterprise value to EBITDA forward metric. The content appears to be a financial data snippet from TradingView, offering a snapshot of this key valuation multiple without further analysis or commentary.
Price to earnings forward of Medpace Holdings, Inc. – LSX:A2APTV
This article provides a financial snapshot of Medpace Holdings, Inc. (LSX:A2APTV) on TradingView, specifically focusing on its forward price-to-earnings ratio. It indicates the market status as closed with no recent trades. The content emphasizes financial data and market information for the company.
Medpace Holdings, Inc. Actuals & Estimates (NASDAQ:MEDP)
Medpace Holdings, Inc. (MEDP) stock has seen significant growth, with a 1.40% increase in the last 24 hours, 12.29% over the past week, and 65.21% over the last year. Analysts have set a price target range of $400.00 to $495.00 for MEDP. The company is scheduled to release its next earnings report on July 22, 2026, and its stock is currently rated as a "strong buy" by technical analysis.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Medpace Holdings, Inc. (MEDP) and Encourages Investors to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has initiated an investigation into Medpace Holdings, Inc. (MEDP) regarding potential claims of corporate wrongdoing by its officers and/or directors. The firm is encouraging investors who purchased Medpace securities before April 22, 2025, and continue to hold them, to come forward and assist in the investigation. The investigation aims to restore investor capital and ensure corporate accountability.
Medpace Holdings, Inc. (MEDP) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential corporate wrongdoing by Medpace Holdings, Inc. (NASDAQ: MEDP). The law firm encourages shareholders who purchased Medpace securities before April 22, 2025, and still hold them, to contact them to assist in the investigation. The firm operates on a contingency fee basis, aiming to restore investor capital and ensure corporate accountability.
How Investors May Respond To Medpace Holdings (MEDP) Joining Turtle Creek’s Clinician-Led CRO Portfolio
Turtle Creek Asset Management recently added Medpace Holdings (MEDP) to its Q1 2026 portfolio, recognizing its clinician-led approach to small and mid-sized biopharma clients and strong cash flow generation. This move reinforces Medpace's established investment narrative, emphasizing its founder-led model and disciplined share repurchases. While this endorsement supports Medpace's high-science model, investors should remain aware of potential concentration risks among its client base.
Medpace (MEDP) Stock Forum and Discussion
The article "Medpace (MEDP) Stock Forum and Discussion" provides an open forum for discussions related to Medpace stock. It serves as a platform for investors and interested parties to share insights, opinions, and analyses regarding the company's financial performance and future outlook.
How Investors May Respond To Medpace Holdings (MEDP) Joining Turtle Creek’s Clinician-Led CRO Portfolio
Turtle Creek Asset Management recently added Medpace Holdings, Inc. (MEDP) to its Q1 2026 portfolio, recognizing the CRO's clinician-led focus on small to mid-sized biopharma clients and strong cash flow. This move reinforces Medpace's existing narrative, emphasizing its founder-led model and disciplined share repurchases, with a near-term focus on backlog conversion as a catalyst and client concentration as a risk. The article suggests investors should consider Medpace's projected 2029 revenue of $3.3 billion and earnings of $615.9 million, which implies a potential fair value of $500.08.
How Investors May Respond To Medpace Holdings (MEDP) Joining Turtle Creek’s Clinician-Led CRO Portfolio
Turtle Creek Asset Management recently added Medpace Holdings (MEDP) to its portfolio, highlighting Medpace's clinician-led focus on small to mid-sized biopharma clients and strong cash flow. This move reinforces Medpace's existing investment narrative, emphasizing its founder-led model, deep scientific expertise, and disciplined share repurchases. Investors should note the company's Q1 2026 revenue of US$706.6 million and net income of US$123.9 million, while also being aware of potential risks like client concentration.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Medpace Holdings, Inc. (MEDP) And Encourages Investors to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Medpace Holdings, Inc. (NASDAQ: MEDP). The investigation focuses on whether Medpace and certain officers engaged in corporate wrongdoing. Investors who bought Medpace securities before April 22, 2025, and still hold them, are encouraged to assist the investigation.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Medpace Holdings, Inc. (MEDP) and Encourages Stockholders to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential corporate wrongdoing by Medpace Holdings, Inc. (MEDP). The firm is encouraging Medpace investors who purchased securities prior to April 22, 2025, and still hold them, to come forward and assist with the investigation. The investigation aims to determine if the company and its officers engaged in misconduct and to restore investor capital.
Medpace Holdings Inc (MEDP) Institutional Confidence
Medpace Holdings Inc (MEDP) has an institutional shareholding score of 7.00, placing it 81st out of 389 in the Biotechnology & Medical Research industry. The institutional shareholding proportion is 85.88%, a slight decrease of 1.23% quarter-over-quarter. James Simons is the largest institutional shareholder, holding 1.77% of outstanding shares.
Medpace Holdings (NasdaqGS:MEDP) Stock Forecast & Analyst Predictions
Medpace Holdings (MEDP) is forecast to grow earnings by 9.4% and revenue by 7.6% annually, with a projected 32.9% return on equity in three years. Despite recent share price volatility and a class-action lawsuit over alleged misleading financial disclosures, analysts expect continued growth. Insider transactions show both sales and option exercises, and recent earnings reports have generally exceeded analyst expectations despite some margin pressures.
What Makes Medpace Holdings (MEDP) an Investment Bet?
Turtle Creek Asset Management highlighted Medpace Holdings, Inc. (NASDAQ: MEDP) in its Q1 2026 investor letter, noting its differentiated strategy focusing on small-to-mid-sized biopharma companies with a full-service offering, unlike its peers who target Big Pharma. Medpace, a clinical contract research organization, has a history of high growth, significant cash flow generation, and opportunistic share repurchases. Despite its strengths, the firm believes some AI stocks offer greater potential for higher and faster returns.
Medpace Holdings Inc (MEDP) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Medpace Holdings Inc (MEDP), listing its major shareholders and their proportionate holdings, including Medpace Investors, L.L.C., BlackRock Institutional Trust Company, N.A., and AQR Capital Management, LLC. It also breaks down shareholder types, institutional shareholding trends over reporting periods, and the company's inclusion in various ETFs. The content provides a comprehensive overview of who owns MEDP and how institutional investment in the company has evolved.
Press Release: Medpace Holdings, Inc. to Report Second Quarter 2026 Financial Results on July 22, 2026
Medpace Holdings, Inc. announced that it will report its second-quarter 2026 financial results on Wednesday, July 22, 2026. Following the release, the company will host a conference call and webcast to discuss the results. Investors can access the event via webcast or dial-in.
Medpace Holdings Inc (MEDP) Earnings Forecast: Future EPS & Revenue Growth Estimates
Medpace Holdings Inc (MEDP) has an earnings forecast score of 6.71, ranking 323 out of 388 in its industry. Analysts have set an average price target of $567.50, with a high of $655.00 and a low of $302.21, and most analysts rate the stock as "Hold". The company's expected revenue for the next quarter is $690.07 million, and EPS is forecasted at $3.97, following a previous quarter EPS of $4.78 against an expectation of $4.35.
Medpace Holdings, Inc. to report Q2 2026 results on July 22
Medpace Holdings, Inc. announced it will release its second quarter 2026 financial results after market close on Wednesday, July 22, 2026. A conference call to discuss these results is scheduled for July 23, 2026, at 9:00 a.m. ET, requiring advance registration. The company is a global clinical contract research organization specializing in Phase I-IV clinical development services.
Medpace (MEDP) Suffers a Larger Drop Than the General Market: Key Insights
Medpace (MEDP) closed down 1.26% on the most recent trading day, underperforming the S&P 500, which lost 0.57%. Despite this short-term dip, the stock has gained 11.13% over the past month, surpassing both the Medical sector and the S&P 500. Investors are now focused on upcoming earnings, with EPS projected to increase by 31.61% and revenue by 12.47% from the prior year's quarter.
Medpace Holdings, Inc. to Report Second Quarter 2026 Financial Results on July 22, 2026
Medpace Holdings, Inc. (Nasdaq: MEDP) announced it will report its second quarter 2026 financial results after market close on Wednesday, July 22, 2026. The company will also host a conference call on Thursday, July 23, 2026, at 9:00 a.m. ET to discuss these results. Interested parties can register in advance for the call via a provided link or access the webcast and supplemental presentation on Medpace's investor relations website.
Medpace Holdings, Inc. To Report Second Quarter 2026 Financial Results On July 22, 2026
Medpace Holdings, Inc. announced it will report its second-quarter 2026 financial results on July 22, 2026. The brief notification was published by Refinitiv and does not provide further details regarding the results themselves.
Medpace Holdings, Inc. to Report Second Quarter 2026 Financial Results on July 22, 2026
Medpace Holdings, Inc. (Nasdaq: MEDP) announced it will report its second quarter 2026 financial results after market close on Wednesday, July 22, 2026. A conference call to discuss these results will be held on Thursday, July 23, 2026, at 9:00 a.m. ET. Interested parties can register in advance for the call or access the webcast and a supplemental slide presentation via the "Investors" section of Medpace's website.
Bronstein, Gewirtz & Grossman, LLC Encourages Medpace Holdings, Inc. (MEDP) Investors to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Medpace Holdings, Inc. (MEDP) regarding possible corporate wrongdoing. The firm encourages investors who purchased Medpace securities before April 22, 2025, and still hold them, to contact them to assist with the investigation. The firm operates on a contingency fee basis and aims to restore investor capital and ensure corporate accountability.
MEDP Financials: Revenue Breakdown, Margins & Competitor Comparison
Medpace Holdings Inc (MEDP) generates significant revenue from its Metabolic segment, contributing 33.6% of total sales. The company demonstrates strong profitability with a gross margin of 26.81%, an operating margin of 20.03%, and a net margin of 17.53%, alongside a Return on Equity of 77.25%. MEDP, with a market capitalization of $13.35 billion, competes with industry leaders like WSE and RTO, with its gross margin being a key comparative metric.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Medpace Holdings, Inc. (MEDP) And Enc
Bronstein, Gewirtz & Grossman, LLC has initiated an investigation into potential claims against Medpace Holdings, Inc. (NASDAQ:MEDP) concerning alleged corporate wrongdoing by its officers and directors. The firm is encouraging investors who purchased Medpace securities before April 22, 2025, and still hold them, to join the investigation. The representation of investors in class actions is on a contingency fee basis.
Madison Small Cap Fund Increased Medpace Holdings (MEDP), Downplaying AI Fears
The Madison Small Cap Fund increased its stake in Medpace Holdings (MEDP) despite the stock pulling back due to AI disruption fears. The fund believes these fears are overblown, arguing that AI will enhance drug development efficiency and increase demand for clinical research services, benefiting larger CROs like Medpace. While Medpace is not among their top AI stock picks, the fund maintains enthusiasm for its investment and selectively added to its position.
Cerity Partners LLC Buys 23,530 Shares of Medpace Holdings, Inc. $MEDP
Cerity Partners LLC increased its stake in Medpace Holdings, Inc. by 41% during the fourth quarter, purchasing 23,530 additional shares and bringing its total holdings to 80,973 shares valued at approximately $45.5 million. This increase comes as Medpace reported strong quarterly earnings, with EPS of $4.28 and revenue of $706.6 million, exceeding analyst expectations. Despite positive financial results, analyst sentiment remains mixed, and company insiders have recently sold shares.
Franklin Resources Inc. Has $168.20 Million Stake in Medpace Holdings, Inc. $MEDP
Franklin Resources Inc. significantly increased its stake in Medpace Holdings, Inc. by 158.6% in Q4, reaching a value of $168.2 million. Medpace reported stronger-than-expected Q1 results, with EPS and revenue surpassing analyst estimates. Despite positive earnings, insider sales by executives and a "Hold" rating from analysts with an average price target of $467.08 suggest a mixed outlook for the stock.
Bank of New York Mellon Corp Has $89.57 Million Holdings in Medpace Holdings, Inc. $MEDP
Bank of New York Mellon Corp decreased its stake in Medpace Holdings, Inc. by 3.5% in the fourth quarter, yet still holds 159,477 shares valued at $89.57 million. Institutional investors own 77.98% of Medpace, while company insiders have recently sold significant portions of their shares. Despite strong recent earnings, analysts rate the stock as a "Hold" due to an ongoing class-action lawsuit.
Bronstein, Gewirtz & Grossman LLC Urges Medpace Holdings, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Medpace Holdings, Inc. (NASDAQ: MEDP) and certain officers, alleging violations of federal securities laws. The lawsuit claims Medpace made materially false and misleading statements about its book-to-bill ratio between April 22, 2025, and February 9, 2026, portraying an overly optimistic outlook despite internal information. Investors who suffered losses during this period are encouraged to join the case, with the deadline to request lead plaintiff status being June 8, 2026.
MEDP DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Medpace (MEDP) Investors of Securities Class Action Deadline on June 8, 2026
Faruqi & Faruqi, LLP is reminding investors of the June 8, 2026 deadline to seek lead plaintiff status in a federal securities class action against Medpace Holdings, Inc. (NASDAQ: MEDP). The lawsuit alleges that Medpace made overly positive statements about its backlog cancellation rates while concealing adverse facts, leading to a significant stock price drop following the announcement of its Q4 2025 book-to-bill ratio of 1.04, which was below guidance. Investors who suffered losses are encouraged to contact the firm to learn more about their legal options.
MEDP DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Medpace (MEDP) Investors of Securities Class Action Deadline on June 8, 2026
Faruqi & Faruqi, LLP is investigating potential securities claims against Medpace Holdings, Inc. (NASDAQ: MEDP) and is reminding investors that the deadline to seek the role of lead plaintiff in a federal securities class action is June 8, 2026. The lawsuit alleges that Medpace made misleading statements and concealed material adverse facts regarding its backlog cancellation rate, which resulted in a significant stock price decline after the company announced a lower-than-guidance book-to-bill ratio in February 2026. Investors with the largest financial interest in the class action are encouraged to contact Faruqi & Faruqi.
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Highlights Class Action Against Medpace Holdings (MEDP) and Upcoming Lead Plaintiff Deadline of June 8, 2026
Faruqi & Faruqi, LLP announced a class action lawsuit against Medpace Holdings (NASDAQ: MEDP), urging investors to seek lead plaintiff status by the June 8, 2026 deadline. The lawsuit alleges that Medpace made false and misleading statements about its backlog cancellation rates and exaggerated growth expectations, leading to a significant stock price drop after disappointing Q4 2025 book-to-bill ratio results. Investors who suffered losses are encouraged to contact the firm for more information.
INVESTOR DEADLINE: Medpace Holdings Inc. (MEDP) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Robbins Geller Rudman & Dowd LLP has announced a class action lawsuit against Medpace Holdings Inc. for alleged violations of the Securities Exchange Act of 1934. Investors who purchased MEDP common stock between April 22, 2025, and February 9, 2026, and suffered substantial losses, have until June 8, 2026, to seek appointment as lead plaintiff. The lawsuit claims Medpace made false and misleading statements regarding its projected book-to-bill ratio and the impact of cancellations.
How Investors Are Reacting To Medpace Holdings (MEDP) Executive Shakeup Amid Securities Class Action Surge
Medpace Holdings (MEDP) recently appointed Brad W. Hansman as Executive Vice President, Operations, sharing leadership responsibilities. This executive change comes as the company faces a surge in securities class action lawsuits alleging misleading statements regarding backlog cancellations and book-to-bill projections. Investors are now evaluating how these legal challenges might impact Medpace's investment narrative and perceived risk, despite the company's solid revenue and earnings growth projections in outsourced clinical trials.
MEDP UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Medpace (MEDP) Investors of Securities Class Action Deadline on June 8, 2026
Faruqi & Faruqi, LLP reminds investors who purchased Medpace (MEDP) securities between April 22, 2025, and February 9, 2026, of the June 8, 2026, deadline to seek lead plaintiff status in a federal securities class action lawsuit. The lawsuit alleges that Medpace issued false and misleading statements regarding its backlog cancellation rates and growth expectations, which led to a significant stock price decline after announcing a book-to-bill ratio below guidance. Investors are encouraged to contact the law firm to discuss their legal options.
Medpace Holdings' high P/E ratio may not be justified given its average growth outlook, potentially leaving shareholders exposed to a price correction. Investors should be cautious, as the stock appears overvalued relative to expected earnings.
Medpace Holdings (NASDAQ:MEDP) appears overvalued, with its high P/E ratio not justified by its average growth outlook. This situation could expose shareholders to a price correction. Investors are advised to be cautious due to the stock's potential overvaluation relative to expected earnings.
